Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, Gainesville.
Center for Drug Evaluation and Safety, University of Florida, Gainesville.
J Gerontol A Biol Sci Med Sci. 2020 Apr 17;75(5):1010-1016. doi: 10.1093/gerona/glz120.
Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor blockers (ARBs) may protect against aging-related decline. This study directly compared ACEis and ARBs on associations with risk of mobility disability in older adults when combined with a physical activity intervention.
This was a secondary analysis of the Lifestyle Interventions and Independence for Elders (LIFE) trial. Participants aged 70-89 years were randomized to a physical activity or health education intervention. Outcomes included incident and persistent major mobility disability, injurious falls, short physical performance battery, and gait speed. For this analysis, only participants who reported ACEi or ARB use at baseline were included. Baseline differences between ACEi and ARB groups were adjusted for using inverse probability of treatment weights. Weighted Cox proportional hazard models and analysis of covariance models were used to evaluate the independent effects of medications and interaction effects with the intervention on each outcome.
Of 1,635 participants in the Lifestyle Interventions and Independence for Elders study, 796 used either an ACEi (496, 62.3%) or ARB (300, 37.7%). Compared with ACEi users, ARB users had 28% lower risk (hazard ratio [HR] = 0.72 [0.60-0.85]) of incident major mobility disability and 35% (HR = 0.65 [0.52-0.82]) lower risk of persistent major mobility disability whereas no interaction between medication use and intervention was observed. Risk of injurious falls and changes in short physical performance battery or gait speed were not different between ARB and ACEi users.
These results suggest that ARBs may protect from major mobility disability by other mechanisms than improving physical performance.
血管紧张素转换酶抑制剂(ACEi)和血管紧张素受体阻滞剂(ARB)可能有助于预防与衰老相关的功能下降。本研究直接比较了 ACEi 和 ARB 与结合体力活动干预的老年人移动性残疾风险之间的关联。
这是生活方式干预和老年人独立(LIFE)试验的二次分析。年龄在 70-89 岁的参与者被随机分配到体力活动或健康教育干预组。结局包括新发和持续的主要移动性残疾、伤害性跌倒、简短体能表现电池和步态速度。本分析仅纳入基线时报告使用 ACEi 或 ARB 的参与者。使用治疗逆概率加权(inverse probability of treatment weights)调整 ACEi 和 ARB 组之间的基线差异。使用加权 Cox 比例风险模型和协方差分析模型评估药物的独立作用以及与干预的相互作用对每种结局的影响。
在生活方式干预和老年人独立研究中,共有 1635 名参与者,其中 796 名使用 ACEi(496 名,62.3%)或 ARB(300 名,37.7%)。与 ACEi 使用者相比,ARB 使用者新发主要移动性残疾的风险降低 28%(风险比 [HR] = 0.72 [0.60-0.85]),持续主要移动性残疾的风险降低 35%(HR = 0.65 [0.52-0.82]),而未观察到药物使用与干预之间的相互作用。ARB 和 ACEi 使用者的伤害性跌倒风险和简短体能表现电池或步态速度变化无差异。
这些结果表明,ARB 通过改善身体表现以外的机制可能预防主要的移动性残疾。